Cost of Revenue Comparison: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.

Biotech Cost Analysis: Corcept vs. BioCryst

__timestampBioCryst Pharmaceuticals, Inc.Corcept Therapeutics Incorporated
Wednesday, January 1, 2014122000882000
Thursday, January 1, 201518960001361000
Friday, January 1, 201626990002058000
Sunday, January 1, 201717020003554000
Monday, January 1, 20184710005215000
Tuesday, January 1, 201941010005504000
Wednesday, January 1, 202016760005582000
Friday, January 1, 202172640005281000
Saturday, January 1, 202265940005385000
Sunday, January 1, 202346610006481000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue: A Tale of Two Biotechs

In the competitive world of biotechnology, understanding cost structures is crucial. This chart compares the cost of revenue for Corcept Therapeutics Incorporated and BioCryst Pharmaceuticals, Inc. over the past decade. Corcept Therapeutics has consistently maintained a higher cost of revenue, peaking in 2023 with a 6% increase from the previous year. Meanwhile, BioCryst Pharmaceuticals saw a significant spike in 2021, with costs rising by 57% compared to 2020, before stabilizing in subsequent years.

Key Insights

  • Corcept Therapeutics: From 2014 to 2023, Corcept's cost of revenue grew by approximately 635%, reflecting its expanding operations and market reach.
  • BioCryst Pharmaceuticals: Despite fluctuations, BioCryst's costs increased by about 3,720% over the same period, highlighting its aggressive growth strategy.

This analysis provides a window into the financial strategies of these two biotech firms, offering valuable insights for investors and industry analysts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025